KNSA
Price:
$20.57
Market Cap:
$1.49B
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin cond...[Read more]
Industry
Biotechnology
IPO Date
2018-05-25
Stock Exchange
NASDAQ
Ticker
KNSA
According to Kiniksa Pharmaceuticals, Ltd.’s latest financial reports and current stock price. The company's current ROE is -2.08%. This represents a change of 287.02% compared to the average of -0.54% of the last 4 quarters.
The mean historical ROE of Kiniksa Pharmaceuticals, Ltd. over the last ten years is 35.57%. The current -2.08% ROE has changed -105.85% with respect to the historical average. Over the past ten years (40 quarters), KNSA's ROE was at its highest in in the December 2017 quarter at 36.45%. The ROE was at its lowest in in the September 2022 quarter at -45.13%.
Average
35.57%
Median
38.32%
Minimum
-37.27%
Maximum
93.16%
Discovering the peaks and valleys of Kiniksa Pharmaceuticals, Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual ROE = 93.16%
Minimum Annual Increase = -259.38%
Minimum Annual ROE = -37.27%
Year | ROE | Change |
---|---|---|
2023 | 3.21% | -108.61% |
2022 | -37.27% | -259.38% |
2021 | 23.38% | -25.02% |
2020 | 31.19% | -31.39% |
2019 | 45.46% | -14.47% |
2018 | 53.15% | -26.51% |
2017 | 72.32% | -22.38% |
The current ROE of Kiniksa Pharmaceuticals, Ltd. (KNSA) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-3.56%
5-year avg
13.19%
10-year avg
35.57%
Kiniksa Pharmaceuticals, Ltd.’s ROE is greater than Nuvalent, Inc. (-28.63%), greater than Ventyx Biosciences, Inc. (-54.94%), greater than Arcellx, Inc. (-8.28%), greater than Cullinan Oncology, Inc. (-26.54%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Structure Therapeutics Inc. (-16.40%), greater than Karuna Therapeutics, Inc. (-25.23%), less than Phathom Pharmaceuticals, Inc. (211.43%), greater than Replimune Group, Inc. (-53.12%), greater than Nuvectis Pharma, Inc. (-155.80%), greater than Lyra Therapeutics, Inc. (-178.68%), greater than Kronos Bio, Inc. (-64.55%), greater than Gossamer Bio, Inc. (-127.28%), greater than Cogent Biosciences, Inc. (-70.85%), greater than Larimar Therapeutics, Inc. (-35.87%), greater than Kura Oncology, Inc. (-44.09%), greater than Cerevel Therapeutics Holdings, Inc. (-98.94%), less than Spero Therapeutics, Inc. (3.36%), greater than Bolt Biotherapeutics, Inc. (-69.46%), less than Coherus BioSciences, Inc. (0.40%), greater than Gracell Biotechnologies Inc. (-15.56%), greater than Neoleukin Therapeutics, Inc. (-8.54%),
Company | ROE | Market cap |
---|---|---|
-28.63% | $5.97B | |
-54.94% | $162.63M | |
-8.28% | $4.10B | |
-26.54% | $671.66M | |
-22.40% | $1.27B | |
-16.40% | $1.62B | |
-25.23% | $12.60B | |
211.43% | $492.32M | |
-53.12% | $940.25M | |
-155.80% | $91.77M | |
-178.68% | $11.46M | |
-64.55% | $57.32M | |
-127.28% | $192.57M | |
-70.85% | $839.24M | |
-35.87% | $250.12M | |
-44.09% | $693.65M | |
-98.94% | $8.19B | |
3.36% | $51.79M | |
-69.46% | $19.13M | |
0.40% | $164.75M | |
-15.56% | $989.87M | |
-8.54% | $8.20M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kiniksa Pharmaceuticals, Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Kiniksa Pharmaceuticals, Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Kiniksa Pharmaceuticals, Ltd.'s ROE?
How is the ROE calculated for Kiniksa Pharmaceuticals, Ltd. (KNSA)?
What is the highest ROE for Kiniksa Pharmaceuticals, Ltd. (KNSA)?
What is the 3-year average ROE for Kiniksa Pharmaceuticals, Ltd. (KNSA)?
What is the 5-year average ROE for Kiniksa Pharmaceuticals, Ltd. (KNSA)?
How does the current ROE for Kiniksa Pharmaceuticals, Ltd. (KNSA) compare to its historical average?